胰高血糖素样肽-1受体激动剂治疗炎症性肠病的安全性和有效性。

IF 8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

American Journal of Gastroenterology Pub Date : 2025-05-01 Epub Date: 2024-11-14 DOI:10.14309/ajg.0000000000003208

Scott R Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak

{"title":"胰高血糖素样肽-1受体激动剂治疗炎症性肠病的安全性和有效性。","authors":"Scott R Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak","doi":"10.14309/ajg.0000000000003208","DOIUrl":null,"url":null,"abstract":"Introduction: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.Methods: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.Results: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.Discussion: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"1152-1155"},"PeriodicalIF":8.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.\",\"authors\":\"Scott R Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak\",\"doi\":\"10.14309/ajg.0000000000003208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.Methods: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.Results: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.Discussion: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.\",\"PeriodicalId\":7608,\"journal\":{\"name\":\"American Journal of Gastroenterology\",\"volume\":\" \",\"pages\":\"1152-1155\"},\"PeriodicalIF\":8.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ajg.0000000000003208\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ajg.0000000000003208","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰高血糖素样肽受体激动剂（GLP1-RA）在炎症性肠病（IBD）患者中的安全性和有效性尚不清楚。方法：回顾性分析GLP1-RA治疗的IBD患者的不良事件、体重变化、临床、内窥镜和生物标志物反应。结果：在120例IBD患者中，胃肠道副作用最为常见（11.5%）。西马鲁肽的减重效果最为显著。1年后c -反应蛋白水平下降（P = 0.005）。在ibd相关住院或内窥镜评分方面没有观察到差异。讨论：在IBD患者中，GLP1-RA治疗安全有效，伴有相关的c反应蛋白降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.

Introduction: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.

Methods: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.

Results: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.

Discussion: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Gastroenterology 医学-胃肠肝病学

CiteScore

11.40

自引率

5.10%

发文量

458

审稿时长

12 months

期刊介绍： Published on behalf of the American College of Gastroenterology (ACG), The American Journal of Gastroenterology (AJG) stands as the foremost clinical journal in the fields of gastroenterology and hepatology. AJG offers practical and professional support to clinicians addressing the most prevalent gastroenterological disorders in patients.